Predictions
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€388.00
05.05.23
05.05.23
€395.00
05.05.24
05.05.24
3.52%
12.05.23
12.05.23
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Seagen Inc.
Start price
Target price
Perf. (%)
€165.90
15.08.22
15.08.22
€180.00
31.01.24
31.01.24
9.64%
08.05.23
08.05.23
Could be very worthwhile Investment >20% year
Merck KGaA
Start price
Target price
Perf. (%)
€190.20
23.01.23
23.01.23
€175.00
23.04.23
23.04.23
-12.41%
23.04.23
23.04.23
Some uniques
Future proof or reliable business model
overvalued
Low dividend yield expected
Sarepta Therapeutics
Start price
Target price
Perf. (%)
€76.43
02.04.22
02.04.22
€90.00
02.04.23
02.04.23
67.74%
03.04.23
03.04.23
Seagen Inc.
Start price
Target price
Perf. (%)
€152.08
07.09.22
07.09.22
€180.00
31.12.24
31.12.24
21.00%
21.03.23
21.03.23
Could be very worthwhile Investment >20% year
Novo Nordisk A/S ADR
Start price
Target price
Perf. (%)
€92.20
28.02.22
28.02.22
€110.00
28.02.23
28.02.23
46.96%
28.02.23
28.02.23
.JPG?locale=us "montechristo681")
Novo Nordisk A/S
Start price
Target price
Perf. (%)
€86.20
20.01.22
20.01.22
€125.00
20.01.23
20.01.23
47.29%
02.01.23
02.01.23
Biogen Inc.
Start price
Target price
Perf. (%)
€208.25
27.12.21
27.12.21
€215.00
27.12.22
27.12.22
23.82%
28.12.22
28.12.22
Could be worthwhile Investment >10% per year
Johnson & Johnson
Start price
Target price
Perf. (%)
€140.70
27.11.21
27.11.21
€160.00
27.11.22
27.11.22
21.35%
28.11.22
28.11.22
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Astrazeneca ADR
Start price
Target price
Perf. (%)
€50.60
27.11.21
27.11.21
€60.00
27.11.22
27.11.22
26.48%
28.11.22
28.11.22
Could be worthwhile Investment >10% per year
Significant cyclical dependencies
Regeneron Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€533.60
09.11.21
09.11.21
€600.00
09.11.22
09.11.22
38.91%
10.11.22
10.11.22
Could be worthwhile Investment >10% per year
Eli Lilly Corp.
Start price
Target price
Perf. (%)
€338.70
07.10.22
07.10.22
€350.00
07.10.23
07.10.23
7.12%
29.10.22
29.10.22
Higher EBIT margin than peer group
Differentiated customer and product portfolio
Medium risks for its business
Top 10 in its market
Gilead Sciences Inc
Start price
Target price
Perf. (%)
€59.87
15.05.22
15.05.22
€68.00
15.05.23
15.05.23
32.12%
28.10.22
28.10.22
Could be worthwhile Investment >10% per year
positive Cash Flow expected
ROE higher than 15% per year
Normal challenges to pay loans and raise capital
Vertex Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€158.36
17.06.21
17.06.21
€165.00
17.06.22
17.06.22
59.60%
18.06.22
18.06.22
Could be worthwhile Investment >10% per year
